Skip to main content
Phase 1 Study of SC291, a Hypoimmune, Allogeneic CD19-Directed CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies (ARDENT) - Initial Clinical Data Neelapu, S. S., Budde, L., McGuirk, J. P., Dahiya, S., Deol, A., Thompson, P. A., Jain, N., Lunning, M. A., Hu, X., Gorovits, B., Quarles, D., Metallo, B., Flaherty, M., Zhang, W., Kouros-Mehr, H., Fry, T. J., Schrepfer, S. AMER SOC HEMATOLOGY. 2023

View details for DOI 10.1182/blood-2023-179441

View details for Web of Science ID 001159900806221